Tadataka Yamada, 1945-2021: Pioneer in drug development led global health at Gates Foundation geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Scout Bio to Present at the BofA Securities 2021 Animal Health Summit
Scout BioFebruary 18, 2021 GMT
PHILADELPHIA, Feb. 18, 2021 (GLOBE NEWSWIRE) Scout Bio, a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions, today announced that Mark Heffernan, Scout Bio’s Chief Executive Officer, will present at the upcoming BofA Securities 2021 Animal Health Summit on Thursday, February 25, 2021 at 2:35 p.m. ET.
About Scout Bio Scout Bio is a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions. Scout Bio’s therapeutics are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology. Scout Bio has a research and development collaboration with the University of P
Scout Bio to Present at the BofA Securities 2021 Animal Health Summit globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Frazier Healthcare Partners Makes Promotions on Life Sciences Team
Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team.
These are Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate.
Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of Phathom Pharmaceuticals and as a member of the board of directors for Scout Bio.
Anna Chen, Ph.D., joined Frazier in 2018 and focuses on evaluating investment opportunities and creating new ventures in the life sciences sector. She is a board observer for Amunix Pharmaceuticals and Inipharm.